This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 290035 results found since Jan 2013.

Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Abstract In total, ~85% of malignant gastrointestinal stromal tumours (GISTs) harbour activating mutations in one of the genes KIT or PDGFRA, while 10‑15% of all GISTs have no detectable KIT or PDGFRA mutations, but could have alterations in genes of the succinate dehydrogenase complex or in BRAF, PIK3CA or rarely RAS family genes. The clinical benefit of tyrosine kinase inhibitors, such as imatinib, depends on the GIST genotype, therefore molecular characterization of GIST has a crucial role in overall management of GIST. The aim of the present study was to molecularly characterize a cohort of 70 patients wi...
Source: International Journal of Oncology - March 25, 2020 Category: Cancer & Oncology Authors: Bombac A, Zakotnik B, Bucic M, Setrajcic Dragos V, Gazic B, Stegel V, Klancar G, Novakovic S Tags: Int J Oncol Source Type: research

MDCT of primary, locally recurrent, and metastatic duodenal gastrointestinal stromal tumours (GISTs): A single institution study of 25 patients with review of literature
Conclusion: Duodenal GISTs are well-circumscribed, round or oval masses, and occur in the second through fourth portions of the duodenum, without lymphadenopathy or duodenal obstruction. Duodenal GISTS metastasize frequently to the liver and peritoneum.
Source: Clinical Radiology - October 25, 2013 Category: Radiology Authors: J.M. Cheng, S.H. Tirumani, A.B. Shinagare, J.P. Jagannathan, J.L. Hornick, C.P. Raut, N.H. Ramaiya Tags: Original Papers Source Type: research

Transgastric submucosal excision of small- to medium-sized gastrointestinal stromal tumours by pure minimally invasive approach
Conclusion: We conclude that a single and common approach of transgastric submucosal excision of small- to medium-sized stromal tumours with 1 cm margin having different locations in upper two-third of stomach, by pure minimally invasive approach, has a better outcome and brings a uniformity in laparoscopic management of GIST.
Source: Journal of Minimal Access Surgery - December 11, 2017 Category: Surgery Authors: Manash Ranjan Sahoo Sumeet Deshpande Shameel Ahmmed Source Type: research

Intestinal occlusion by stenotic neuroendocrine tumours of left colon and concomitant association with small bowel gastrointestinal stromal tumours: a case report
ConclusionConcomitant NEC and GIST is rare but it is important to investigate patients before surgery in order to distinguish these from other tumours because of the different prognosis.
Source: International Journal of Surgery Case Reports - October 27, 2018 Category: Surgery Source Type: research

Cancers, Vol. 15, Pages 1285: Endoscopic Ultrasound Advanced Techniques for Diagnosis of Gastrointestinal Stromal Tumours
useppinella Melita Gastrointestinal Stromal Tumors (GISTs) are subepithelial lesions (SELs) that commonly develop in the gastrointestinal tract. GISTs, unlike other SELs, can exhibit malignant behavior, so differential diagnosis is critical to the decision-making process. Endoscopic ultrasound (EUS) is considered the most accurate imaging method for diagnosing and differentiating SELs in the gastrointestinal tract by assessing the lesions precisely and evaluating their malignant risk. Due to their overlapping imaging characteristics, endosonographers may have difficulty distinguishing GISTs from other SELs using conven...
Source: Cancers - February 17, 2023 Category: Cancer & Oncology Authors: Socrate Pallio Stefano Francesco Crin ò Marcello Maida Emanuele Sinagra Vincenzo Francesco Tripodi Antonio Facciorusso Andrew Ofosu Maria Cristina Conti Bellocchi Endrit Shahini Giuseppinella Melita Tags: Review Source Type: research

Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours
miR-210 is a key regulator of response to hypoxia. Pheochromocytomas (PCs) and paragangliomas (PGLs) with germline SDHx or VHL mutations have pseudohypoxic gene expression signatures. We hypothesised that PC/PGLs containing SDHx or VHL mutations, and succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumours (GISTs), would overexpress miR-210 relative to non-SDH or -VHL-mutated counterparts. miR-210 was analysed by quantitative PCR in i) 39 PC/PGLs, according to genotype (one SDHA, five SDHB, seven VHL, three NF1, seven RET, 15 sporadic, one unknown) and pathology (18 benign, eight atypical, 11 malignant, two...
Source: Endocrine-Related Cancer - May 6, 2014 Category: Endocrinology Authors: Tsang, V. H. M., Dwight, T., Benn, D. E., Meyer-Rochow, G. Y., Gill, A. J., Sywak, M., Sidhu, S., Veivers, D., Sue, C. M., Robinson, B. G., Clifton-Bligh, R. J., Parker, N. R. Tags: Research Source Type: research

Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases
Conclusion The management of GISTs has considerably evolved during the last years. Surgical resection, which remains the mainstay of treatment, was indicated in the majority of patients. Imatinib treatment has not improved overall survival in metastatic and/or inoperable cases.
Source: Arab Journal of Gastroenterology - December 7, 2016 Category: Gastroenterology Source Type: research

Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply an aggressive behaviour
ConclusionsRhabdoid gastric GISTs are associated with epithelioid morphology and PDGFRA mutations. They harbour CGH aberrations typical of ordinary GISTs in both tumour components. Presence of additional genetic alterations in the rhabdoid areas indicates a genetic evolution from the epithelioid components and possible genetic and biologic progression. Based on our series and previous reports, rhabdoid morphology in GISTs presumably doesn't imply aggressiveness.This article is protected by copyright. All rights reserved.
Source: Histopathology - August 27, 2013 Category: Pathology Authors: Inga‐Marie Schaefer, Philipp Ströbel, Silke Cameron, Alexander Beham, Claudia Otto, Hans‐Ulrich Schildhaus, Abbas Agaimy Tags: Original Article Source Type: research

Rhabdoid morphology in gastrointestinal stromal tumours (GISTs) is associated with PDGFRA mutations but does not imply aggressive behaviour
ConclusionsRhabdoid gastric GISTs are associated with epithelioid morphology and PDGFRA mutations. They harbour CGH aberrations that are typical of ordinary GISTs in both tumour components. The presence of additional genetic alterations in the rhabdoid areas indicates evolution from the epithelioid components, and possible genetic and biological progression. On the basis of our series and previous reports, rhabdoid morphology in GISTs presumably does not imply aggressiveness.
Source: Histopathology - November 22, 2013 Category: Pathology Authors: Inga‐Marie Schaefer, Philipp Ströbel, Silke Cameron, Alexander Beham, Claudia Otto, Hans‐Ulrich Schildhaus, Abbas Agaimy Tags: Original Article Source Type: research

The role of 68  GaGa-DOTATATE PET/CT in wild-type KIT / PDGFRA gastrointestinal stromal tumours (GIST)
ConclusionsOur data suggest that SSTR2 is not a diagnostic or therapeutic target in wtGIST. [68 Ga]Ga-DOTATATE PET/CT may have specific diagnostic utility in differentiating wtGIST from other primary tumours such as paraganglioma in patients with sporadic and hereditary forms of wtGIST.
Source: EJNMMI Research - January 14, 2021 Category: Radiology Source Type: research

Gastrointestinal Stromal Tumours Bigger than 20 cm: Experience with Imatinib Chemotherapy in Neoadjuvant Intention.
Abstract The size of the primary tumour is considered the most important risk factor for the development of metastasis or local recurrence in case of gastrointestinal stromal tumour (GIST). Until now no prospective data are available in the literature about the role of neadjuvant therapy with Imatinib. Between 2009 and 2012 seven patients with a giant GIST > 20 cm underwent a neadjuvant treatment with Imatinib, a radical operation, followed by an adjuvant therapy. These patients were controlled with regard to peri- and postoperative morbidity and disease-free survival. Two patients were considered not resec...
Source: Zeitschrift fur Gastroenterologie - January 1, 2014 Category: Gastroenterology Authors: Girotti P, Rolinger J, Kopp HG, Königsrainer A, Ladurner R Tags: Z Gastroenterol Source Type: research

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumours (GIST) or soft tissue sarcoma (STS).
CONCLUSIONS: In patients progressing on imatinib/sunitinib, cediranib 45 mg/day demonstrated evidence of activity by 18FDG-PET but did not reduce average SUVmax. Evidence of antitumor activity was seen in ASPS. PMID: 24714778 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 8, 2014 Category: Cancer & Oncology Authors: Judson IR, Scurr M, Gardner K, Barquin E, Marotti M, Collins B, Young H, Jurgensmeier J, Leahy M Tags: Clin Cancer Res Source Type: research

Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumours: rationale and efficacy.
Conclusions: IMA+PI3Ki has significant anti-tumour efficacy in GIST xenografts as compared to single agent treatment, resulting in more prominent tumour volume reduction and enhanced induction of apoptosis. Categorization of GIST based on KIT genotype and PI3K/PTEN genomic status combined with dose optimization is suggested for patient selection for clinical trials exploring such combinations. PMID: 25316817 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 14, 2014 Category: Cancer & Oncology Authors: Van Looy T, Wozniak A, Floris G, Sciot R, Li H, Wellens J, Ulla V, Fletcher JA, Manley PW, Debiec-Rychter M, Schoffski P Tags: Clin Cancer Res Source Type: research

Gastrointestinal Stromal Tumours (GIST) - development in pathology, surgery and medical therapy.
Abstract The first description of ligand-independent activating mutations in the KIT gene, which encodes the tyrosine-kinase KIT, greatly improved our understanding of gastrointestinal stromal tumour (GIST) biology. The therapeutic success in GIST has made tyrosine kinase inhibitors a "paradigm of targeted therapy". Deciphering resistance mechanisms in GIST has had implications for many other kinase-driven cancers. To exchange current knowledge within the field of GIST, the German GIST Meeting has taken place for now 10 years, traditionally in Göttingen. Subjects discussed include clinical diagnostics, pathology,...
Source: Zeitschrift fur Gastroenterologie - March 1, 2015 Category: Gastroenterology Authors: Agaimy A, Bauer S, Beham A, Bertolini J, Haller F, Koschny R, Maier J, Montemurro M, Perez D, Schaefer IM, Schildhaus HU, Wurst C, Cameron S Tags: Z Gastroenterol Source Type: research

Definition and clinical significance of tumour rupture in gastrointestinal stromal tumours of the small intestine.
CONCLUSION: Recurrence rates were increased after major, but not minor tumour ruptures. PMID: 26988241 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - March 14, 2016 Category: Surgery Authors: Hølmebakk T, Bjerkehagen B, Boye K, Bruland Ø, Stoldt S, Sundby Hall K Tags: Br J Surg Source Type: research